Umamaheswari Ramachandran

Array ( [id] => 13519617 [patent_doc_number] => 20180311351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB [patent_app_type] => utility [patent_app_number] => 16/023161 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519613 [patent_doc_number] => 20180311349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB [patent_app_type] => utility [patent_app_number] => 16/023046 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519615 [patent_doc_number] => 20180311350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB [patent_app_type] => utility [patent_app_number] => 16/023152 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16504880 [patent_doc_number] => 20200384136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => COMPOSITION COMPRISING CATALASE, PREPARATION METHOD AND USE THEREOF AND METHOD FOR KILLING TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 16/606976 [patent_app_country] => US [patent_app_date] => 2018-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618835 [patent_doc_number] => 20180360969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => IMMUNOGLOBULIN PREPARATION [patent_app_type] => utility [patent_app_number] => 16/009670 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3528 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590059 [patent_doc_number] => 20180346578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/009865 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18273642 [patent_doc_number] => 11612562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Solution preparation containing stabilized antibody [patent_app_type] => utility [patent_app_number] => 16/008486 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 11292 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18558750 [patent_doc_number] => 11723975 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody [patent_app_type] => utility [patent_app_number] => 16/616583 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 17 [patent_no_of_words] => 34473 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16589195 [patent_doc_number] => 10898436 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions [patent_app_type] => utility [patent_app_number] => 15/988501 [patent_app_country] => US [patent_app_date] => 2018-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 17 [patent_no_of_words] => 8370 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15988501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551899 [patent_doc_number] => 20180327497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY [patent_app_type] => utility [patent_app_number] => 15/983791 [patent_app_country] => US [patent_app_date] => 2018-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35863 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15983791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467817 [patent_doc_number] => 20190185551 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2019-06-20 [patent_title] => METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS [patent_app_type] => utility [patent_app_number] => 15/982990 [patent_app_country] => US [patent_app_date] => 2018-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15982990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467817 [patent_doc_number] => 20190185551 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2019-06-20 [patent_title] => METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS [patent_app_type] => utility [patent_app_number] => 15/982990 [patent_app_country] => US [patent_app_date] => 2018-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15982990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16642118 [patent_doc_number] => 10919954 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Antigen binding dimer-complexes, methods of making/avoiding and uses thereof [patent_app_type] => utility [patent_app_number] => 15/976928 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 44069 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15976928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19809735 [patent_doc_number] => 12241107 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Method of controlling the pink color generated during antibody manufacturing [patent_app_type] => utility [patent_app_number] => 16/612175 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 12002 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16791712 [patent_doc_number] => 20210121529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => STABLE HYBRID FC FUSION G-CSF FORMULATION [patent_app_type] => utility [patent_app_number] => 17/052696 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253548 [patent_doc_number] => 20200262922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/609671 [patent_app_country] => US [patent_app_date] => 2018-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16609671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14145469 [patent_doc_number] => 10253093 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => Human monoclonal antibodies against interleukin 8 (IL-8) [patent_app_type] => utility [patent_app_number] => 15/966533 [patent_app_country] => US [patent_app_date] => 2018-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 25470 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15966533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18341917 [patent_doc_number] => 11639391 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Stable liquid pharmaceutical composition [patent_app_type] => utility [patent_app_number] => 16/604031 [patent_app_country] => US [patent_app_date] => 2018-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 6244 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13339897 [patent_doc_number] => 20180221488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 15/936047 [patent_app_country] => US [patent_app_date] => 2018-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37830 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15936047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18246834 [patent_doc_number] => 11603407 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-14 [patent_title] => Stable antibody formulation [patent_app_type] => utility [patent_app_number] => 15/927783 [patent_app_country] => US [patent_app_date] => 2018-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 30016 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15927783 [rel_patent_id] =>[rel_patent_doc_number] =>)